
Currently out of the existing stock ratings of Justin Zelin, 119 are a BUY (97.54%), 3 are a HOLD (2.46%).
Analyst Justin Zelin, currently employed at BTIG, has had 20% of price targets met with an average potential upside of 40.36%, reached in 94 days on average.
Justin Zelin has documented 230 price targets and ratings displayed on 33 stocks. The coverage is on Healthcare, Industrials, Energy, Technology sectors.
Most recent stock forecast was given on IBRX, Immunitybio at 23-Jan-2026.
Analyst best performing recommendations are on IBRX (IMMUNITYBIO).
The best stock recommendation documented was for VKTX (VIKING THERAPEUTICS) on 2/8/2024. The price target of $36 was fulfilled within 8 days with a profit of $7.11 (24.61%), with a performance score of 30.76.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Oct-2017
$18
$15.58 (643.80%)
$20
10 days ago
(12-Nov-2026)
0/21 (0%)
$15.71 (686.03%)
Buy Since 08-Nov-2022
$30
$27.58 (1139.67%)
$28
2 months 4 days ago
(18-Sep-2026)
1/8 (12.5%)
$24.43 (438.60%)
1
Buy Since 17-Mar-2026
$21
$18.58 (767.77%)
$22
3 months 8 days ago
(14-Aug-2026)
0/2 (0%)
$15.01 (250.58%)
Buy Since 29-Apr-2025
$17
$14.58 (602.48%)
$19
8 months 5 days ago
(17-Mar-2026)
0/4 (0%)
$12.24 (257.14%)
Buy Since 02-Jun-2025
$22
$19.58 (809.09%)
$20
8 months 13 days ago
(09-Mar-2026)
0/3 (0%)
$16.84 (326.36%)
Stocks Justin Zelin covered previously. Scores are shown for active stocks only.
The record of these past calls is part of the data set at anachart.store.
What Year was the first public recommendation made by Justin Zelin?